This study should provide insight into the glycaemic control benefits of chiglitazar and suggests that RBP-4 may be a potential metabolic health biomarker for the evaluation of T2DM and a therapeutic target for T2DM patients. This evidence concerns the gene RBP4 and type 2 diabetes mellitus.